Novartis AG annual dividends paid
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Novartis AG Dividends Paid Growth & History (NVS)
Novartis AG paid $7.82B in dividends during fiscal 2025.
View full Novartis AG company overviewNovartis AG annual dividends paid history
| Fiscal year | Period ended | Dividends paid | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.82B | $194.0M | +2.54% |
| 2024 | 2024-12-31 | $7.62B | $369.0M | +5.09% |
| 2023 | 2023-12-31 | $7.25B | −$251.0M | −3.34% |
| 2022 | 2022-12-31 | $7.51B | $138.0M | +1.87% |
| 2021 | 2021-12-31 | $7.37B | $381.0M | +5.45% |
| 2020 | 2020-12-31 | $6.99B | $342.0M | +5.15% |
| 2019 | 2019-12-31 | $6.64B | −$321.0M | −4.61% |
| 2018 | 2018-12-31 | $6.97B | $471.0M | +7.25% |
| 2017 | 2017-12-31 | $6.50B | $20.0M | +0.31% |
| 2016 | 2016-12-31 | $6.47B | — | — |
Novartis AG quarterly dividends paid
Q2.24
Q1.25
Q2.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Dividends paid | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.87B | $386.0M | +15.53% |
| Q1 2026 | 2026-03-31 | $6.20B | $864.0M | +16.20% |
| Q4 2025 | 2025-12-31 | $0 | — | — |
| Q2 2025 | 2025-06-30 | $2.48B | $68.0M | +2.81% |
| Q1 2025 | 2025-03-31 | $5.33B | — | — |
| Q2 2024 | 2024-06-30 | $2.42B | — | — |
Novartis AG dividends paid trends
Over the last five fiscal years, Novartis AG's dividends paid increased from $6.99B to $7.82B, a change of $831.0M. The latest reported quarter, Q2 2026, shows $2.87B.
About the metric
What dividends paid mean
Dividends paid are cash distributions made to shareholders. The history shows the company’s aggregate cash outflow for dividends, not the dividend per share, dividend yield, or the date an investor receives a payment.
Calculation and source
Reported cash dividends paid
TickerStat standardizes cash dividends paid to common or ordinary shareholders from official cash-flow filings. Reported zero-dividend periods remain zero and are not treated as missing data. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...